2-(2-甲基-2-硝基丙基)萘 | 400613-92-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 2-(2-甲基-2-硝基丙基)萘
• 英文名称: 2-(2-methyl-2-nitropropyl)naphthalene
• CAS: 400613-92-5
• 化学式: C₁₄H₁₅NO₂
• 分子量: 229.279
• InChiKey: UOPSIIWJYNGUMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(2-甲基-2-硝基丙基)萘 在 盐酸 、 锌 作用下， 以 乙醇 、 水 为溶剂， 以0.69 g的产率得到2-甲基-1-(萘-2-基)丙胺
  参考文献：
  名称：

  Synthesis of the calcilytic ligand NPS 2143

  摘要：

  (R)-3（NPS 2143）是人类钙感受受体（CaSR）的负向变构调节剂，因此代表了一个重要的药理学工具化合物，用于研究CaSR。在此，我们首次披露了对(R)-3的完整实验描述，详细表征和对对映体纯度的评估。我们提出了一种高效、可重复和可扩展的(R)-3合成方法，只需要最少的色谱纯化步骤。通过手性HPLC表明(R)-3的光学纯度非常高（er > 99:1），而且(R)-3的药理学特性完全符合文献报道。

  DOI：

  10.3762/bjoc.9.154
• 作为产物：
  描述：

  2-萘甲腈 在 lithium aluminium tetrahydride 、 sodium methylate 作用下， 以 乙醚 、 乙醇 、 甲苯 为溶剂， 反应 18.33h， 生成 2-(2-甲基-2-硝基丙基)萘
  参考文献：
  名称：

  Synthesis of the calcilytic ligand NPS 2143

  摘要：

  (R)-3（NPS 2143）是人类钙感受受体（CaSR）的负向变构调节剂，因此代表了一个重要的药理学工具化合物，用于研究CaSR。在此，我们首次披露了对(R)-3的完整实验描述，详细表征和对对映体纯度的评估。我们提出了一种高效、可重复和可扩展的(R)-3合成方法，只需要最少的色谱纯化步骤。通过手性HPLC表明(R)-3的光学纯度非常高（er > 99:1），而且(R)-3的药理学特性完全符合文献报道。

  DOI：

  10.3762/bjoc.9.154

文献信息

• Calcium receptor antagonist
  申请人：——

  公开号：US20040006130A1

  公开（公告）日：2004-01-08

  A compound of the formula [I] 1 wherein R 1 is optionally substituted aryl group or optionally substituted heteroaryl group; R 2 is optionally substituted C 1-6 alkyl group, C 3-7 cycloalkyl group and the like; R 3 is hydrogen atom, C 1-6 alkyl group, hydroxyl group and the like; R 4 is hydrogen atom, C 1-6 alkyl group and the like; R 5 and R 6 are each C 1-6 alkyl group and the like; R 7 is optionally substituted aryl group or optionally substituted heteroaryl group; X 1 , X 2 and X 3 are each C 1-6 alkylene group and the like; and X 4 and X 5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.

  式为[I]的化合物，其中R1是可选择取代的芳基或可选择取代的杂环基；R2是可选择取代的C1-6烷基、C3-7环烷基等；R3是氢原子、C1-6烷基、羟基等；R4是氢原子、C1-6烷基等；R5和R6分别是C1-6烷基等；R7是可选择取代的芳基或可选择取代的杂环基；X1、X2和X3分别是C1-6亚烷基等；X4和X5分别是单键、亚甲基基团等，提供其盐、溶剂合物或前药，以及含有该化合物的药物组合物，特别是一种钙受体拮抗剂和治疗骨质疏松症的药物。本发明的化合物可用作伴有异常钙稳态或骨质疏松症、甲状旁腺功能减退症、骨肉瘤、牙周病、骨折、骨关节炎、慢性类风湿关节炎、帕盖特病、体液性高钙血症、常染色体显性低钙血症等疾病的治疗药物。此外，还提供了该化合物的中间体。
• Calcium receptor antagonists
  申请人：Shinagawa Yuko

  公开号：US20050107448A1

  公开（公告）日：2005-05-19

  A compound of the formula [I] wherein R 1 is optionally substituted aryl group or optionally substituted heteroaryl group; R 2 is optionally substituted C 1-6 alkyl group, C 3-7 cycloalkyl group and the like; R 3 is hydrogen atom, C 1-6 alkyl group, hydroxyl group and the like; R 4 is hydrogen atom, C 1-6 alkyl group and the like; R 5 and R 6 are each C 1-6 alkyl group and the like; R 7 is optionally substituted aryl group or optionally substituted heteroaryl group; X 1 , X 2 and X 3 are each C 1-6 alkylene group and the like; and X 4 and X 5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.

  本发明提供了式[I]的化合物，其中R1是可选取代芳基或可选取代杂环基；R2是可选取代C1-6烷基、C3-7环烷基等；R3是氢原子、C1-6烷基、羟基等；R4是氢原子、C1-6烷基等；R5和R6分别是C1-6烷基等；R7是可选取代芳基或可选取代杂环基；X1、X2和X3分别是C1-6亚烷基等；X4和X5分别是单键、亚甲基等。本发明还提供了该化合物的盐、溶剂化物或前药，以及包含该化合物的药物组合物，特别是钙受体拮抗剂和治疗骨质疏松症的药物。本发明的化合物可用作伴随异常钙稳态或骨质疏松症、低副甲状腺素血症、骨肉瘤、牙周病、骨折、骨关节炎、慢性类风湿性关节炎、帕盖特病、体液性高钙血症、常染色体显性低钙血症等疾病的治疗药物。此外，还提供了该化合物的中间体。
• Catalytic Generation of Radicals from Nitroalkanes
  作者：Kohei Kosaka、Naoki Matsushita、Yoshiaki Nakao、Myuto Kashihara、Shunta Notsu、Ayumi Osawa

  DOI：10.1055/a-1942-0683

  日期：——

  A new protocol for the catalytic denitrative generation of radicals from nitroalkanes was disclosed. 9-Fluorenol acts as a single-electron transfer catalyst that reduces nitroalkanes to promote the C-NO2 bond cleavage, followed by the formation of alkyl radicals. The obtained radicals participate in diverse transformations such as hydrogenation, Giese addition, spirocyclization, and Minisci reactions

  公开了一种从硝基烷烃催化脱硝产生自由基的新方案。9-芴醇作为一种单电子转移催化剂，可还原硝基烷烃以促进 C-NO 2键断裂，然后形成烷基自由基。获得的自由基通过使用适当的捕获试剂参与多种转化，例如氢化、吉斯加成、螺环化和 Minisci 反应。本系统在成本、毒性和实验操作方面优于使用氢化锡的传统方法。
• CALCIUM RECEPTOR ANTAGONISTS
  申请人：Japan Tobacco Inc.

  公开号：EP1308436B1

  公开（公告）日：2008-10-15
• Chemoenzymatic synthesis of calcilytic agent NPS-2143 employing a lipase-mediated resolution protocol
  作者：Ahmed Kamal、Gagan Chouhan

  DOI：10.1016/j.tetasy.2005.07.022

  日期：2005.8

  The kinetic resolution of chlorohydrin (+/-)-6 has been successfully carried out via a lipase-mediated transesterification with vinyl acetate in organic as well as ionic liquid media to yield (R)-alcohol 6 and (S)-acetate 7 in high enantioselectivity. An enantioconvergent synthesis has also been achieved by a Mitsunobu esterification of a mixture of (R)-alcohol 6 and (S)-acetate 7 in one pot to convert the (R)-alcohol 6 to (S)-acetate 7. (S)-Acetate 7 has been hydrolyzed by LiOH center dot H2O to give epoxide (R)-2. This enantiopure epoxide has been used as a chiral precursor for the synthesis of calcilytic agent NPS-2143. (c) 2005 Elsevier Ltd. All rights reserved.